SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
Home > Boards > US Listed > Biotechs >

Aurinia Pharmaceuticals Inc (AUPH)

AUPH RSS Feed
Add AUPH Price Alert      Hide Sticky   Hide Intro
Moderator: Jesspro
Search This Board: 
Last Post: 9/19/2017 5:26:39 PM - Followers: 144 - Board type: Free - Posts Today: 6

Aurinia is a late-stage biopharmaceutical company providing novel products specifically engineered to treat a limited, targeted patient population suffering from serious disease states for which there is a high unmet medical need.

*Aurinia Pharmaceuticals Inc.
http://www.auriniapharma.com/
 

Pipeline

 

Pipeline

Pipeline

Candidate & Indication Development Stage
Preclinical Phase 1 Phase 2 Phase 3 Market
VOCLOSPORINLupus Nephritis (LN)
Preclinical Phase complete
Phase 1 Phase complete
Phase 2 Phase in progress
Phase 3 Phase not started
Market Phase not started

Aurinia is committed to working in areas of high unmet medical need and is poised to deliver the first approved therapy in the U.S. and Europe for the treatment of lupus nephritis, or LN.

The Voclosporin Advantage

Voclosporin, an investigational drug, is a novel and potentially best-in-class calcineurin inhibitor (“CNI”) with clinical data in over 2,000 patients across indications. Voclosporin is an immunosuppressant, with a synergistic and dual mechanism of action that has the potential to improve near- and long-term outcomes in lupus nephritis (LN) when added to standard of care mycophenolate mofetil (MMF). It has been granted “fast track status” by the U.S. Food & Drug Administration (FDA).

Voclosporin Could Transform the LN treatment Landscape

Voclosporin has the potential to become a best in class medication and the first approved treatment for LN in the U.S. and Europe, effectively altering the current treatment paradigm for the disease.

Advantages of Voclosporin Combined with Standard of Care (SoC)

Our clinical data suggests that adding voclosporin to the current SoC of MMF for the treatment of lupus nephritis (LN) will yield superior results to using the standard of care alone.

Additionally, voclosporin may prove to be an ideal therapy for lupus nephritis due to advantages such as:

  • Improved efficacy
    Increased safety
    Oral administration
    Improved average time to renal response or remission
    Improved duration of renal response
    Reduction in steroid burden
    Potential first line add-on to MMF
    Fewer toxic immunosuppressants required
Benefits of Voclosporin

Potential Benefits of Voclosporin

In clinical trials, Voclosporin has been shown to be especially effective in the presence of low dose steroids with rapid reduction of LN inflammatory markers and overall improved renal stability.

The list of potential product benefits includes:

LN Critical Need Voclosporin (based on AURA Results)
Control of Active Disease
Rapid Disease Control
Lower Steroid Burden
Impact on Extra-renal disease
Convenient Treatment Regimen

In previous studies, over 2000 patients have been treated with Voclosporin with no abnormal or unexpected SAE’s

Well Characterized Safety Profile

Efficacy of calcineurin inhibition has already been established. Voclosporin has a well-characterized safety profile (over 2,000 patient exposures across multiple years) across indications.

No new safety signals were observed with the use of Voclosporin in LN patients; Voclosporin was well-tolerated and renal function remained stable in clinical studies. The overall safety profile is consistent with other immunosuppressive drugs.

 

SureTrader
Cannabis Stocks News
Interactive Brokers Advertisement
AUPH
Current Price
Volume:
Bid Ask Day's Range
  • 1D
  • 1M
  • 2M
  • 3M
  • 6M
  • 1Y
  • 2Y
  • 3Y
  • 5Y
News News Alert: Report of Foreign Issuer (6-k) 09/19/2017 04:10:24 PM
PostSubject
#4884  Sticky Note AUPH: Now that Ph3 for LN is underway Lunacy aka John Galt 07/19/17 06:05:27 PM
#5526   New additional indications to be provided on Oct 20th somerssalt 09/19/17 05:26:39 PM
#5525   Indeed BR, indeed. Maciste 09/19/17 04:23:35 PM
#5524   Maciste, indeed, you are catching on..... biotech_researcher 09/19/17 03:24:02 PM
#5523   Indeed. Maciste 09/19/17 03:18:40 PM
#5522   On pogo sticks and fly backs! Hotrodder1 09/19/17 03:00:12 PM
#5521   This is dreary.. Heading still lower....where is the bounce? biotech_researcher 09/19/17 02:10:46 PM
#5519   72sites https://clinicaltrials.gov/ct2/show/NCT03021499?term=Voclosporin&rank=3 LivingTheDream 09/18/17 10:20:18 AM
#5518   "....utter nonsense and just guesses" moosedogger 09/18/17 04:15:05 AM
#5517   Too many bury their head in the sand biotech_researcher 09/16/17 10:06:30 PM
#5512   You think there is value here? Could have SvsB 09/16/17 12:06:55 AM
#5511   No, I expect there is value here as biotech_researcher 09/15/17 11:00:08 PM
#5510   Indeed BR, perhaps the time has come for Maciste 09/15/17 10:52:16 PM
#5509   Price targets are utter nonsense and just guesses. biotech_researcher 09/15/17 09:59:35 PM
#5508   misleading/inaccurate as usual. You forgot to add moosedogger 09/15/17 08:57:38 PM
#5507   "Looking ahead, Arce “project[s] top-line AURORA results at biotech_researcher 09/15/17 07:52:07 PM
#5505   Thanks moose this could finally be the year Maciste 09/14/17 11:31:15 AM
#5503   Amen, Brother! trading_cyclist 09/14/17 09:50:20 AM
#5502   Nope- it's really the constant lying, misrepresentation, stupidity, moosedogger 09/14/17 05:59:30 AM
#5501   Jess, great observation. Anything that is stated that biotech_researcher 09/14/17 05:51:41 AM
#5500   You guys are so easy to get provoked. Jesspro 09/13/17 10:12:27 PM
#5499   Aurinia Falls On Misinterpreted 'Downgrade' somerssalt 09/13/17 09:58:28 PM
#5498   That downgrade took the wind out of her sails.. zzaatt 09/13/17 04:07:30 PM
#5497   The way this is now running, it appears biotech_researcher 09/13/17 02:03:20 PM
#5496   Maciste- BTW, congrats on the Indians- 20 straight! moosedogger 09/13/17 12:19:07 PM
#5495   A very frightening thought! I applaud your courage! moosedogger 09/13/17 11:23:44 AM
#5492   downgraded to speculative, someone is a bit behind cervelo 09/13/17 10:13:19 AM
#5491   And another Canaccord analyst said this in March: moosedogger 09/13/17 10:01:57 AM
#5490   TC- per usual, carb issued misleading/incorrect info moosedogger 09/13/17 09:50:35 AM
#5489   Peekaboo!! trading_cyclist 09/13/17 08:24:40 AM
#5488   Aw shucks, thanks for the kind words!! trading_cyclist 09/13/17 08:22:41 AM
#5487   Peek at ph 3?? biotech_researcher 09/13/17 08:04:20 AM
#5486   News for 'AUPH' - (DJ Aurinia Pharmaceuticals Cut biotech_researcher 09/13/17 08:01:42 AM
#5485   OH, THE HUMANITY!!! SantaFe Miguel 09/12/17 11:42:52 PM
#5483   It is running, just the wrong way. cervelo 09/12/17 02:40:08 PM
#5482   Brutal day to hold AUPH. Thought it would run.... biotech_researcher 09/12/17 02:38:08 PM
#5481   Hope you enjoyed the trip! I hear great SvsB 09/12/17 12:29:08 PM
#5479   That was totally warranted. He was abusive. Pencow 09/11/17 10:18:18 PM
#5478   Svsb - "Dust off your Panda hat". SantaFe Miguel 09/11/17 09:41:07 PM
#5477   Thank you Moderators!!! Hotrodder1 09/11/17 09:38:21 AM
#5476   Aurinia Pharmaceuticals Inc somerssalt 09/11/17 07:53:29 AM
#5475   A couple things stand out to me that Lunacy aka John Galt 09/10/17 08:06:33 PM
#5474   Is $AUPH's lupus nephritis hegemony threatened by $GSK's zzaatt 09/10/17 12:47:05 PM
#5473   IBD says that AUPH develops drugs for treatment Pencow 09/10/17 11:13:46 AM
#5472   JG, did you see the following? seventhwave 09/10/17 04:20:20 AM
#5468   AUPH has very bright future. Patience is the grandma_of_jbraika 09/10/17 02:45:02 AM
#5467  Restored I don't set stop loss. I don't buy grandma_of_jbraika 09/10/17 02:44:49 AM
#5465   AUPH CEO Glickman says $4 billion market by grandma_of_jbraika 09/10/17 02:44:38 AM
#5460   Dust off your Panda hat! SvsB 09/09/17 04:38:16 PM
#5457   Totally agree with ya'll as far as Carb SantaFe Miguel 09/08/17 09:13:59 PM
#5452   Not a bad premise. Maybe we could start SvsB 09/08/17 12:13:05 PM
PostSubject